Anshen-Buxin-Liuwei pill, a Mongolian medicinal formula could alleviate cardiomyocyte hypoxia/reoxygenation injury via mitochondrion pathway

• Published in: Molecular biology reports Vol. 49; no. 2; pp. 885 - 894
• Main Authors: Huang, Yu-Jia, Tong, Hai‑Ying, Huang, Xian‑Ju, Xiao, Xin-Cai, Dong, Yue, Iqbal, Muhammad Sarfaraz
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.02.2022; Springer Nature B.V
• Subjects: Angina; Angina pectoris; Animal Anatomy; Animal Biochemistry; Animals; Annexin V; Antioxidants; Apoptosis; Apoptosis - drug effects; Arrhythmia; Biomedical and Life Sciences; Ca2+-transporting ATPase; Cardiomyocytes; Cardiovascular disease; Cardiovascular diseases; Cell Hypoxia - drug effects; Cell injury; Cell Line; Cell Survival - drug effects; Cell viability; Cholecystokinin; Coronary artery disease; Cytochrome c; Cytochromes c - metabolism; Energy metabolism; Heart diseases; Histology; Hypoxia; Hypoxia - metabolism; Ischemia; Life Sciences; Medicine, East Asian Traditional - methods; Mitochondria; Mitochondria - metabolism; Morphology; mRNA; Myocardial Reperfusion Injury - drug therapy; Myocardial Reperfusion Injury - prevention & control; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Na+/K+-exchanging ATPase; Original Article; Oxidative Stress - drug effects; Rats; Sirtuin 3 - metabolism; Mitochondrion pathway; Coronary heart disease; Traditional Mongolian medicine; Hypoxia/reoxygenation; Anshen-Buxin-Liuwei pill
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-021-06867-z

Background Anshen Buxin Liuwei pill (ABLP) is a Mongolian medicinal formula that is composed of six medicinal materials: the Mongolian medicine Bos taurus domesticus Gmelin, Choerospondias axillaris (Roxb.) Burtt et Hill, Myristica fragrans Houtt., Eugenia caryophμllata Thunb., Aucklandia lappa Decne., and Liqui dambar formosana Hance. ABLP is considered to have a therapeutic effect on symptoms such as coronary heart disease, angina pectoris, arrhythmia, depression and irritability, palpitation, and shortness of breath. Methods H9c2 cardiomyocytes were used to construct a hypoxia/reoxygenation (HR) injury model. CCK-8 assay and Annexin V-FITC cell apoptosis assays were used for cell viability and cell apoptosis determination. The LDH, SOD, MDA, CAT, CK, GSH-Px, Na + -K + -ATPase, and Ca 2+ -ATPase activities in cells were determined to assess the protective effects of ABLP. The mRNA levels of Sirtuin3 (Sirt3) and Cytochrome C (Cytc) in H9c2 cells were determined by quantitative real-time PCR. Results The results indicate that HR-treated cells began to shrink from the spindle in an irregular shape with some floated in the medium. By increasing the therapeutic dose of ABLP (5, 25, and 50 μg/mL), the cells gradually reconverted in a concentration-dependent manner. The release of CK in HR-treated cells was significantly increased, indicating that ABLP exerts a protective effect in H9c2 cells against HR injury and can improve mitochondrial energy metabolism and mitochondrial function integrity. The present study scrutinized the cardioprotective effects of ABLP against HR-induced H9c2 cell injury through antioxidant and mitochondrial pathways. Conclusions ABLP could be a promising therapeutic drug for the treatment of myocardial ischemic cardiovascular disease. The results will provide reasonable information for the clinical use of ABLP. Graphic abstract